Abstract:Glioblastoma multiforme (GBM) is the most prevalent central nervous system malignancy portending dismal prognosis. The median overall survival (OS) is 14.6 months with currently available standard care of surgery, radiotherapy and Temozolomide (TMZ) chemotherapy. TMZ, which is the best chemotherapeutic drug till date for this malignancy, gives a median OS advantage of only 2.5 months over surgery and radiotherapy alone. It is not clear how the benefit of TMZ is severely limited in a large majority of patients.… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.